Gsk (GLAXF) Interest & Investment Income (2009 - 2026)

Gsk's Interest & Investment Income history runs 18 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 56.39% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $29.7 million (down 56.39% YoY), while the FY2025 annual figure was $222.8 million, up 42.88% from the prior year.
• Interest & Investment Income was $29.7 million for Q1 2026 at Gsk, down from $175.4 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $175.4 million in Q3 2025 to a low of $9.4 million in Q1 2022.
• Historically, Interest & Investment Income has averaged $61.9 million across 5 years, with a median of $41.3 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income soared 968.62% in 2022, then sank 56.39% in 2026.
• A 5-year view of Interest & Investment Income shows it stood at $58.9 million in 2022, then jumped by 84.86% to $108.9 million in 2023, then advanced by 4.96% to $114.3 million in 2024, then jumped by 53.42% to $175.4 million in 2025, then plunged by 83.09% to $29.7 million in 2026.
• The last three Interest & Investment Income figures came in at $29.7 million (Q1 2026), $175.4 million (Q3 2025), and $66.7 million (Q2 2025), per Business Quant data.